Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
about
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapyAdvanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approachesReversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody TherapyWeekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.Thermosensitive Hydrogel Co-loaded with Gold Nanoparticles and Doxorubicin for Effective ChemoradiotherapyTargeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinomaLow-value practices in oncology contributing to financial toxicity.Pharmacologic treatment options for advanced epithelial skin cancer.EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.Epidermal growth factor receptor imaging in human head and neck cancer xenografts.A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants.Non-melanoma skin cancer: new and future synthetic drug treatments.The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).Prognostic and predictive value of EGFR in head and neck squamous cell carcinomaCost analysis of cetuximab (Erbitux) plus radiotherapy (ERT) versus concomitant cisplatin plus radiotherapy (CRT) within an NHS oncology unit (single institution): a pilot study.Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines.Targeted nanoparticles for tumour radiotherapy enhancement-the long dawn of a golden era?CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation.Combination of cetuximab with radio-chemotherapy in patients with esophageal cancer: less is more!EGFR-targeted therapies in the post-genomic era.PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Updates on the Management of Non-Melanoma Skin Cancer (NMSC).Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials.Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.Head and neck cancer in Hong Kong.DNA Repair.Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality ApproachesAppropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
P2860
Q24187274-147D9F94-ABAC-4AD5-900D-12C74EE1387CQ26767046-B701382D-A914-4312-BF29-14FF46BA20FBQ33736664-2D309876-73A1-40A9-BFB3-9AAA16699A04Q36378279-F11D53C3-B1FA-432E-AC9F-635D8C930C9AQ36445146-38F5A36F-8367-4EE1-A6AB-2E4367F7E69FQ36656097-B77AC7C7-EAAC-41E8-8EDA-C39D2C942D34Q36834852-B54CD52A-2E9D-40DE-A5B7-CB6FDBD31A3EQ37720714-F863B50B-417E-402F-9DA7-B43ABBC3DF21Q38509273-D9911209-DBE4-4D7F-A27C-47DBAC2E44C8Q38552978-8118130B-9A45-4C5B-BAE4-CBFE264A9630Q38561772-2744264E-940C-454E-A2BD-2F28F71F8EADQ38683823-4F1BF610-849D-4912-A13E-A62433E1B327Q38729673-2D49D46E-AB31-410A-B8E8-840A1FBC0B47Q38757864-0EF9665E-7B7C-48DD-ABCF-21447C636193Q38854643-187AF082-9408-4FA0-9621-82AF7303DB14Q38935842-FB313358-5EC4-49E9-8DEB-EADDB6211561Q39296776-1BB7DDC6-2691-4660-B206-FB46455DFAFCQ40471529-A532166D-6DA1-4A33-929C-3EAB17C4A0E6Q41667158-0A9F2330-5867-4A0D-A643-1EE888BACAB4Q42330851-5F4E3CFC-A9AF-41BA-825C-0E633FCAE82BQ42363121-8EE5F3AF-4FD0-458A-B476-85FE18A24B2BQ43102462-341DBACC-7FCB-404C-BA91-72C1E1F7D8D0Q45871491-2EFC64A0-401D-46A7-AF5E-2E48F58C962CQ46500151-86479444-FD48-44CD-83FF-2F156A8E1892Q46811811-E040D127-79A1-47D0-908C-CA9F84349378Q46829455-CD3A0421-FE40-422D-9B5A-F1A07414F310Q47103766-49781A08-262A-4CD7-A4BD-3AA71641F5D0Q48226075-C8B99D52-9F8B-424C-8E5C-C1B1A4F88E2EQ48294854-2373F814-7721-4BE8-9F42-E89B9C8A827CQ49960053-FBA5E8E4-FF2D-4464-A0D5-8631329C8C1BQ52863441-0EFC1D2D-0A1E-4CBC-991B-AAB8A17C9260Q53507332-245D7980-D0FF-4888-990C-B5C094F0A0C5Q54982410-D88A97F1-7850-448B-AD64-FAAFEA44F1C3Q57816910-A45E6361-C9D5-493C-8390-29BF4DB96681Q57818008-14B0CE1E-5B86-4D94-AB56-9A81D0DB0437
P2860
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Chemoradiotherapy with or with ...... led, open-label phase 2 trial.
@en
Chemoradiotherapy with or with ...... led, open-label phase 2 trial.
@nl
type
label
Chemoradiotherapy with or with ...... led, open-label phase 2 trial.
@en
Chemoradiotherapy with or with ...... led, open-label phase 2 trial.
@nl
prefLabel
Chemoradiotherapy with or with ...... led, open-label phase 2 trial.
@en
Chemoradiotherapy with or with ...... led, open-label phase 2 trial.
@nl
P2093
P921
P1433
P1476
Chemoradiotherapy with or with ...... led, open-label phase 2 trial.
@en
P2093
Alejandro Cesar Yunes Ancona
Alicia Zhang
Andre Fortin
Anthony Cmelak
Ari VanderWalde
Avi B Markowitz
Jordi Giralt
Kelly S Oliner
Krzysztof Skladowski
Marco C Merlano
P304
P356
10.1016/S1470-2045(14)71198-2
P577
2015-01-15T00:00:00Z